These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25442869)

  • 1. Impact of revised susceptibility breakpoints on bacteremia of Klebsiella pneumoniae: Minimum inhibitory concentration of cefazolin and clinical outcomes.
    Chuang CH; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):679-684. PubMed ID: 25442869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia.
    Wang KC; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):768-774. PubMed ID: 26493889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.
    Chastain DB; Ngando I; Bland CM; Franco-Paredes C; Hawkins WA
    Ann Clin Microbiol Antimicrob; 2017 May; 16(1):43. PubMed ID: 28558707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.
    Chiang TT; Chiang MH; Tang HJ; Shi ZY; Ho MW; Chou CH; Lin SY; Lu PL; Wu TS; Shie SS; Liu JW; Chang FY; Chuang YC; Wang FD; Yang YS
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1777-1785. PubMed ID: 38995342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive Cefazolin Therapy for Stabilized Adults with Community-Onset
    Hsieh CC; Chen PL; Lee CH; Yang CY; Lee CC; Ko WC
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for Cefazolin as De-escalation Therapy for Klebsiella Pneumoniae Bacteraemia.
    Ng TM; Teng CB; Lew EL; Ling LM; Ang B; Lye DC
    Ann Acad Med Singap; 2015 Dec; 44(12):571-4. PubMed ID: 27090077
    [No Abstract]   [Full Text] [Related]  

  • 10. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
    Ratliff AR; Gentry CA; Williams RJ
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
    Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
    Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
    Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another look at differences in the susceptibility of Escherichia coli and Klebsiella pneumoniae to cephalothin and cefazolin.
    Yeh LL; Chi CL
    Int J Antimicrob Agents; 2001 Jun; 17(6):521-4. PubMed ID: 11397625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp.
    Ku NS; Chung HS; Choi JY; Yong D; Lee K; Kim JM; Chong Y
    Biomed Res Int; 2015; 2015():831074. PubMed ID: 25793209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
    Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
    Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
    Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?
    Tamma PD; Wu H; Gerber JS; Hsu AJ; Tekle T; Carroll KC; Cosgrove SE
    Pediatr Infect Dis J; 2013 Sep; 32(9):965-9. PubMed ID: 23470679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing trends in antimicrobial susceptibility of Streptococcus pneumoniae isolates in Taiwan, 2006-2007.
    Li CF; Liu MF; Shi ZY; Hsueh PR; Liao CH; Jang TN; Tsao SM; Kung HC; Hsu GJ; Cheng YJ; Lin HC; Liu YC; Chuang YC; Wang LS; Chen CM
    J Microbiol Immunol Infect; 2012 Aug; 45(4):305-10. PubMed ID: 22608926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibility to first-generation Cephalosporins in Enterobacteriaceae isolated from urine culture according to CLSI and EUCAST breakpoints].
    Corvalán V; Hervé B; Sanhueza C; Martínez N; Almonacid M; Fuente S
    Rev Chilena Infectol; 2018; 35(3):329-331. PubMed ID: 30534916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.